A study of TNG462 combinations with two RAS(ON) inhibitors – RAS(ON) multi-selective inhibitor, RMC-6236, and RAS(ON) G12D-selective inhibitor, RMC-9805 (Revolution Medicines) – osimertinib (AstraZeneca) and pembrolizumab (Merck)

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 17 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Osimertinib (Primary) ; Pembrolizumab (Primary) ; RMC-6236 (Primary) ; RMC-9805 (Primary) ; TNG 462 (Primary)
Indications Cancer; Solid tumours
Focus Adverse reactions; Therapeutic Use

Most Recent Events

17 Nov 2024 New trial record
06 Nov 2024 According to Tango Therapeutics media release, enrollment planned to start in 1H 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight